News

FDA reviewers support approval of platelet inhibitor cangrelor for PCI indication

Publish date: February 10, 2014

 

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Mild coronary artery disease is gender blind
MDedge Cardiology
Higher PCI risk in diabetes not due to insulin
MDedge Cardiology
FDA panel backs approval of novel antiplatelet drug vorapaxar
MDedge Cardiology
FDA panel rejects rivaroxaban again for acute coronary syndrome
MDedge Cardiology
Surgeon General report links smoking to diseases beyond cancer
MDedge Cardiology
Inpatient safety efforts yield mixed results
MDedge Cardiology
Cooling the resuscitated sudden dead
MDedge Cardiology
FDA: Naproxen may pose lower CV risk
MDedge Cardiology
Persistent depression doubled coronary heart disease risk
MDedge Cardiology
Recent data support preventive multivessel PCI in STEMI patients
MDedge Cardiology

Related Articles